{"id":14948,"date":"2011-05-01T09:05:26","date_gmt":"2011-05-01T09:05:26","guid":{"rendered":"http:\/\/i-base.info\/htb\/?p=14948"},"modified":"2011-05-01T09:05:26","modified_gmt":"2011-05-01T09:05:26","slug":"community-resources-and-publications-5","status":"publish","type":"post","link":"https:\/\/i-base.info\/htb\/14948","title":{"rendered":"Community resources and publications"},"content":{"rendered":"<h2>TAG hepatitis C pipeline report<\/h2>\n<p>FDA approval of two hepatitis C-specific protease inhibitors, the first of the coming wave of oral antiviral drugs, is anticipated later this year. Dozens of drugs are in development to fight hepatitis C virus (HCV).<\/p>\n<p>The Treatment Action Group 2011 Hepatitis C Treatment Pipeline Report is a comprehensive overview of drugs in clinical trials. The Pipeline covers a range of issues, including diagnostics, drug resistance, \u00a0access to, and delivery of treatment, and population-specific focus on the new HCV drugs, as well as research recommendations.<\/p>\n<p>Download<br \/>\n<a href=\"http:\/\/cts.vresp.com\/c\/?TreatmentActionGroup\/b5f575334e\/9e21c20d7a\/9ae5755cb4\/id=4416\">http:\/\/cts.vresp.com\/c\/?TreatmentActionGroup\/b5f575334e\/9e21c20d7a\/9ae5755cb4\/id=4416<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>TAG hepatitis C pipeline report FDA approval of two hepatitis C-specific protease inhibitors, the first of the coming wave of oral antiviral drugs, is anticipated later this year. Dozens of drugs are in development to fight hepatitis C virus (HCV). &hellip;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[30],"tags":[],"class_list":["post-14948","post","type-post","status-publish","format-standard","hentry","category-on-the-web"],"_links":{"self":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/comments?post=14948"}],"version-history":[{"count":0,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/posts\/14948\/revisions"}],"wp:attachment":[{"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/media?parent=14948"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/categories?post=14948"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/i-base.info\/htb\/wp-json\/wp\/v2\/tags?post=14948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}